Are Synairgen plc or Immupharma plc better investments than AstraZeneca plc?

Should you invest in juniors Synairgen plc (LON:SNG) and Immupharma plc (LON:IMM) or giant AstraZeneca plc (LON:AZN)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Junior pharmaceutical stocks have the potential to create huge value for shareholders if successful. These two stocks both have drugs that could create many millions of revenue in the future. Will either outperform pharma giant AstraZeneca (LSE: AZN), though?

Respiratory focus

Synairgen (LSE: SNG) is a drug development company founded by three University of Southampton professors, the business focusing on treating respiratory diseases such as asthma. The company has a potential asthma treatment which is being developed with AstraZeneca after signing a licensing and development deal in 2014. The deal is worth up to $232m plus royalties and the drug entered Phase IIa trials in July 2015. Synairgen hopes to release results on the trials sometime in 2017.

The inhaled treatment developed by Synairgen has the potential to be a blockbuster product. Many believe if the drug is approved then AstraZeneca may take over Synairgen to acquire full ownership of the drug. This isn’t the only project in Synairgen’s pipeline: the company recently signed a research collaboration with Pharmaxis to develop a treatment for a fatal lung disease. Chairman Simon Shaw recently commented that “our collaboration with Pharmaxis has begun to yield positive results and we anticipate a Phase I clinical trial in 2017“. 

Lupus treatment

Immupharma (LSE: IMM) is in the process of developing its Lupuzor drug which is currently in Phase III clinical trials at 43 sites across the US and Europe. The company is aiming to release “top line results” by the end of 2017. The potential of the drug is huge and the company thinks the Lupus market has the potential for multi-billion dollar sales. The company made a £3.9m loss last year mainly due to research and development costs which is perfectly normal for a junior pharma stock. Immupharama recently carried out a £8.4m funding round which should fund the company right through to 2018.  It’s clear to me that Immupharama has the potential to make huge returns for shareholders if Lupuzor is brought to the market. Investors should keep an eye on the company next year when initial trial results are expected. 

Exciting pipeline

AstraZeneca is different to the two juniors as it has a pipeline full of new and exciting drugs going through clinical trials. The company pays a chunky 4.8% dividend and trades on an attractive 14.2 times earnings. AstraZeneca has the firepower to make acquisitions in the future which should boost earnings and keep the company moving forward with new drugs and treatments. The defensive qualities of the stock should mean it holds up well after the EU referendum on the 23rd June, and investors looking to shelter cash should take a serious look at the company. Although AstraZeneca is unlikely to give you the huge gains that are possible with Synairgen and Immupharma, it could be a great core holding for the long term. 

Investing in junior pharma stocks is a risky game. The rewards could be massive, but most drugs never make it to market and companies can lose millions in research and development. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jack Dingwall has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black father holding daughter in a field of cows
Investing Articles

£25k of savings? Consider aiming for a £1k+ monthly passive income via this strategy

With a long-term mindset, investors could target a four-figure monthly passive income by investing £25k in low-volatility blue-chip stocks.

Read more »

Investing Articles

The Rolls-Royce share price hit new highs in November. What next?

November has been another record-breaking month for the Rolls-Royce share price. And the outlook for 2025 still looks bright.

Read more »

Investing Articles

Here’s the growth forecast for Sage Group shares to 2026!

Sage Group shares have rocketed following the tech firm's stunning third-quarter update. Is now the time to consider buying in?

Read more »

Investing Articles

10%+ dividend growth! 2 FTSE 250 shares tipped to turbocharge dividends

These FTSE 250 income shares look in great shape to grow their dividends by double-digit percentages, says our writer Royston…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

Would it be madness to buy this FTSE stock smashed by Donald Trump’s team picks?

Ben McPoland takes a look at one FTSE share inside his portfolio that has been battered lately due to a…

Read more »

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »